Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Alpha Synuclein (SNCA) Drugs in Development Report Overview

Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.

The pipeline report covers the descriptive pharmacological action and product description of SNCA. It includes the complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in SNCA therapeutic development and features dormant and discontinued products.

Buy the Full Report to Know More about the SNCA Pipeline Products

Download a Free Report Sample

Key Therapy Areas ·        Central Nervous System

·        Metabolic Disorders

·        Cardiovascular

·        Gastrointestinal

·        Infectious Disease

·        Ophthalmology

Key Indications ·        Parkinson’s Disease

·        Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

·        Lewy Body Dementia

·        Alzheimer’s Disease

·        Neurodegenerative Diseases

Key Mechanisms of Action ·        Alpha Synuclein Inhibitor
Key Routes of Administration ·        Oral

·        Intravenous

·        Subcutaneous

·        Intrathecal

·        Nasal

Key Molecule Types ·        Small Molecule

·        Monoclonal Antibody

·        Gene Therapy

·        Fusion Protein

·        Antibody

Leading Companies ·        AC Immune SA

·        ABL Bio Inc

·        Alterity Therapeutics Ltd

·        Annovis Bio Inc

·        Aprinoia Therapeutics Inc

Enquiry & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

SNCA Pipeline Products Segmentation by Therapy Areas

The key therapy areas associated with SNCA drugs in development are the central nervous system, metabolic disorders, cardiovascular, gastrointestinal, infectious disease, and ophthalmology. The central nervous system therapy area had the highest share among SNCA drugs in development in 2022.

SNCA Pipeline Products Analysis by Therapy Areas, 2022 (%)

SNCA Pipeline Products Analysis by Therapy Areas, 2022 (%)

Buy the Full Report for More Therapy Area Insights into the SNCA Pipeline Products

Download a Free Report Sample

SNCA Pipeline Products Segmentation by Indications

A few of the key indications for SNCA drug application include Parkinson’s disease, multiple system atrophy (MSA or Shy-Drager syndrome or multi-system degeneration), Lewy body dementia, Alzheimer’s disease, and neurodegenerative diseases, among others. Alpha Synuclein drugs had the highest number of products in development for Parkinson’s disease in 2022.

SNCA Pipeline Products Analysis by Indications, 2022 (%)

SNCA Pipeline Products Analysis by Indications, 2022 (%)

Buy the Full Report for More Indication Insights into SNCA Pipeline Products

Download a Free Report Sample

SNCA Pipeline Products Segmentation by MoA and Molecule Types

The only mechanism of action in SNCA drugs in development is the Alpha Synuclein Inhibitor. A few of the key molecule types associated with SNCA pipeline drugs are small molecule, monoclonal antibody, gene therapy, fusion protein, and antibody. Among them, small molecule had the highest number in the pipeline in 2022.

SNCA Pipeline Products Analysis by Molecule Types, 2022 (%)

SNCA Pipeline Products Analysis by Molecule Types, 2022 (%)

Buy the Full Report for More MoA and Molecule Types Insights into SNCA Pipeline Products

Download a Free Report Sample

SNCA Pipeline Products Segmentation by Routes of Administration

The SNCA drugs can be administered by oral, intravenous, subcutaneous, intrathecal, and nasal routes. Oral RoA was the most preferred way for Alpha Synuclein drug administration in 2022.

SNCA Pipeline Products Analysis by Routes of Administration, 2022 (%)

SNCA Pipeline Products Analysis by Routes of Administration, 2022 (%)

Buy the Full Report for More RoA Insights into SNCA Pipeline Products

Download a Free Report Sample

SNCA Pipeline Products - Competitive Landscape

AC Immune SA had the highest number of products in the SNCA pipeline in 2022

A few of the leading companies associated with SNCA pipeline products are:

  • AC Immune SA
  • ABL Bio Inc
  • Alterity Therapeutics Ltd
  • Annovis Bio Inc
  • Aprinoia Therapeutics Inc

AC Immune SA: AC Immune is headquartered in Lausanne, Switzerland. It is a clinical-stage biopharmaceutical company that discovers, designs, and develops proprietary medicines to prevent, diagnose, and treat neurodegenerative diseases associated with protein misfolding. The company’s technology platforms help it to design, discover, and develop antibodies, small molecules, and vaccines.

SNCA Pipeline Products Analysis by Companies, 2022 (%)

SNCA Pipeline Products Analysis by Companies, 2022 (%)

Buy the Full Report for More Company Insights into SNCA Pipeline Products

Download a Free Report Sample

SNCA Pipeline Products - Featured News

7th November 2022: Alterity Therapeutics is a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases. It announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study. The presentation was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022.

Buy the Full Report to Know More Featured News about SNCA Pipeline Products

Download a Free Report Sample

Segments Covered in the Report

SNCA Pipeline Products Therapy Area Outlook (2022)

  • Central Nervous System
  • Metabolic Disorders
  • Cardiovascular
  • Gastrointestinal
  • Infectious Disease
  • Ophthalmology

SNCA Pipeline Products Indication Outlook (2022)

  • Parkinson’s Disease
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
  • Lewy Body Dementia
  • Alzheimer’s Disease
  • Neurodegenerative Diseases

SNCA Pipeline Products MoA Outlook (2022)

  • Alpha Synuclein Inhibitor

SNCA Pipeline Products RoA Outlook (2022)

  • Oral
  • Intravenous
  • Subcutaneous
  • Intrathecal
  • Nasal

SNCA Pipeline Products Molecule Type Outlook (2022)

  • Small Molecule
  • Monoclonal Antibody
  • Gene Therapy
  • Fusion Protein
  • Antibody

Scope of Report

  • The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA).
  • The report reviews Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The report assesses Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The report reviews the latest news and deals related to Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics.

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

FAQs

  • The central nervous system therapy area had the highest share among SNCA drugs in development in 2022.

  • Alpha Synuclein drugs had the highest number of products in development for Parkinson’s disease in 2022.

  • Oral was the most preferred way for SNCA drug administration in 2022.

  • Small molecule was the leading molecule type for the SNCA drugs in development in 2022.

  • A few of the leading companies associated with the SNCA pipeline products are AC Immune SA, ABL Bio Inc., Alterity Therapeutics Ltd, Annovis Bio Inc., and Aprinoia Therapeutics Inc., among others.

What our clients have to say

More Reports

View More Reports